Address
Paasheuvelweg 25a
Amsterdam, 1105 BP
United States of America (the)
Phone
31 20 240 6000
Website
Sector
Healthcare
Industry
Biotechnology
Employees
209
First IPO Date
February 05, 2014
| Name | Title | Pay | Year Born |
| Matthew Craig Kapusta | Chief Executive Officer & Executive Director | 1.05M | 1972 |
| Jeannette Potts | Chief Legal & Compliance Officer and Corporate Secretary | 712,827 | 1962 |
| Richard Porter | Chief Business & Scientific Officer | 732,169 | 1968 |
| Christian Klemt | Chief Financial Officer, Principal Financial Officer & GM of Amsterdam Site | 759,950 | 1973 |
| Walid Abi-Saab | Chief Medical Officer | 945,278 | 1965 |
| Chiara Elizabeth Russo | Senior Director of Investor Relations | 0 | N/A |
| Amin Abujoub | Chief Technical Operations Officer | 0 | N/A |
| Tamara Tugal | Business Development Director | 0 | N/A |
| Erin Boyer | Chief People & Culture Officer | 0 | N/A |
| Hugo Katus | Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany | 0 | N/A |
| Kylie O'Keefe | Chief Customer & Strategy Officer | 0 | 1985 |
uniQure N.V. operates as a specialized gene therapy company, dedicated to pioneering therapeutic solutions for individuals grappling with severe genetic and other debilitating illnesses. The firm's most advanced project, Etranacogene dezaparvovec (designated as AMT-061), is currently progressing through a crucial Phase III pivotal trial, known as HOPE-B, targeting the treatment of hemophilia B. In addition to its flagship program, uniQure is actively developing several other candidates. This includes AMT-130, a gene therapy undergoing Phase I/II clinical assessment for Huntington's disease, and AMT-060, also in Phase I/II clinical trials for hemophilia B. The company's pipeline further extends to AMT-210 for Parkinson's disease, AMT-260 aimed at temporal lobe epilepsy, and AMT-161, which addresses amyotrophic lateral sclerosis. Furthermore, AMT-240 is an early-stage, preclinical product candidate focused on autosomal dominant Alzheimer's disease. Established in 1998, uniQure N.V. maintains its corporate headquarters in Amsterdam, Netherlands.